A Phase 2 Study of VS-6766 and Defactinib in People with Advanced Mesonephric Gynecologic Cancer

Full Title

Single Arm Phase II Study of Avutometinib (VS-6766) and Defactinib in Advanced or Recurrent Mesonephric Gynecologic Cancer

Purpose

Mesonephric cancer is a rare gynecologic cancer. The purpose of this study is to assess the safety and effectiveness of giving VS-6766 and defactinib together in people with advanced or recurrent mesonephric gynecologic cancers.

VS-6766 and defactinib inhibit enzymes called kinases found on the surface of cancer cells, and cancer cells need these enzymes to survive and grow. When these enzymes are blocked, a cancer may stop growing or grow more slowly, and the cancer cells may shrink. VS-6766 and defactinib are both taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

• Participants must have mesonephric gynecologic cancer that has metastasized or came back after prior therapy.
• At least 4 weeks must pass since the completion of previous anti-cancer treatments and receipt of the study therapy.
• This study is for women age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Rachel Grisham at 646-888-4653.